Breaking News

Omni Bio Appoints Development Officer

May 1, 2014

Forrest brings 25 years of industry experience

Dr. Bruce D. Forrest has been appointed chief development officer at Omni Bio Pharmaceutical, Inc. Dr. Forrest currently serves as president of B D Forrest & Co., Inc., a pharma/biopharma consulting firm that provides scientific strategy and business development support, and has worked with Omni Bio during the past year. 
In his expanded role, he will oversee the development plan for Omni Bio's lead Fc fusion recombinant AAT molecule for the potential treatment of type 1 diabetes, graft versus host disease and various inflammatory conditions. He will also provide leadership for the cell line optimization and product manufacturing partnership with Gallus BioPharmaceuticals, Inc. 
Dr. Forrest has more than 25 years of industry experience in pharmaceutical development, including vaccines and biopharmaceuticals. Dr. Forrest was previously senior vice president in Vaccines R&D at Wyeth Pharmaceuticals, where he was responsible for clinical and development activities for all late phase programs. He also served as head of Wyeth's R&D organization in Japan and held various clinical research roles at Chiron Corp. and United Biomedical, Inc. 
Dr. Bruce E. Schneider, chief executive officer of Omni Bio, said, "We are extremely pleased to have Dr. Forrest serve in this role for Omni Bio. His background as an immunologist and his proven track record in managing both non-clinical and clinical R&D functions will be enormously helpful to us as we pursue the ongoing development of recombinant AAT."
blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments